Given the low confidence intervals due to the small study size (~10,000) in the overseas studies, I don't think the FDA is wrong to wait for enough events (aka

Given the low confidence intervals due to the small study size (~10,000) in the overseas studies, I don't think the FDA is wrong to wait for enough events (aka X people get COVID) in the USA study to more accurately determine effectiveness (30,000 participants, 2/3 with vaccine). That said, I think it's likely safer to consider safety data from those other studies, as that's unlikely to change much based on study size (especially combined with the fact that X million have been distributed overseas).